Low interim influenza vaccine effectiveness, Australia, 1 May to 24 September 2017

Euro Surveill. 2017 Oct;22(43):17-00707. doi: 10.2807/1560-7917.ES.2017.22.43.17-00707.

Abstract

In 2017, influenza seasonal activity was high in the southern hemisphere. We present interim influenza vaccine effectiveness (VE) estimates from Australia. Adjusted VE was low overall at 33% (95% confidence interval (CI): 17 to 46), 50% (95% CI: 8 to 74) for A(H1)pdm09, 10% (95% CI: -16 to 31) for A(H3) and 57% (95% CI: 41 to 69) for influenza B. For A(H3), VE was poorer for those vaccinated in the current and prior seasons.

Keywords: Australia; epidemiology; influenza; influenza-like illness - ILI; surveillance; vaccines and immunisation; viral infections.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Australia / epidemiology
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Influenza A Virus, H1N1 Subtype / genetics
  • Influenza A Virus, H1N1 Subtype / immunology*
  • Influenza A Virus, H1N1 Subtype / isolation & purification
  • Influenza A Virus, H3N2 Subtype / genetics
  • Influenza A Virus, H3N2 Subtype / immunology*
  • Influenza A Virus, H3N2 Subtype / isolation & purification
  • Influenza B virus / genetics
  • Influenza B virus / immunology*
  • Influenza B virus / isolation & purification
  • Influenza Vaccines / administration & dosage*
  • Influenza Vaccines / immunology
  • Influenza, Human / epidemiology*
  • Influenza, Human / prevention & control*
  • Influenza, Human / virology
  • Laboratories
  • Male
  • Middle Aged
  • Outcome Assessment, Health Care
  • RNA, Viral / genetics
  • Seasons
  • Sentinel Surveillance*
  • Sequence Analysis, DNA
  • Vaccination / statistics & numerical data
  • Vaccine Potency*
  • Vaccines, Inactivated / administration & dosage
  • Vaccines, Inactivated / immunology
  • Young Adult

Substances

  • Influenza Vaccines
  • RNA, Viral
  • Vaccines, Inactivated